Moon Lake Immunotherapeutics MLTX
Institutional shares held
55.3 Million
481K
calls
229K
puts
Total value of holdings
$2.68B
$23.3M
calls
$11.1M
puts
Market Cap
$1.79B
36,925,600
Shares Out.
Institutional ownership
149.68%
# of Institutions
161
We take great care to ensure that the data presented and summarized in this overview for MoonLake Immunotherapeutics is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MLTX
View all-
Bvf Inc San Francisco, CA19.8MShares$959 Million33.91% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$412 Million35.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.97MShares$144 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$134 Million1.75% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.48MShares$71.8 Million0.01% of portfolio
-
Westfield Capital Management CO LP Boston, MA1.43MShares$69.7 Million0.29% of portfolio
-
Goldman Sachs Group Inc New York, NY1.29MShares$62.8 Million0.01% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA1.27MShares$61.6 Million0.11% of portfolio
-
Polar Capital Holdings PLC London, X01.1MShares$53.4 Million0.29% of portfolio
-
Alliancebernstein L.P. New York, NY966KShares$46.9 Million0.01% of portfolio
Latest Institutional Activity in MLTX
Top Purchases
Top Sells
About MLTX
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Insider Transactions at MLTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 27
2025
|
Matthias Bodenstedt Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
95,763
+13.44%
|
-
|
|
Feb 27
2025
|
Da Silva Jorge Santos Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
95,763
+3.02%
|
-
|
|
Jan 20
2025
|
Kristian Reich Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
111,949
-57.02%
|
-
|
|
Jan 20
2025
|
Kristian Reich Chief Scientific Officer |
BUY
Conversion of derivative security
|
Direct |
111,949
+42.11%
|
-
|
|
Oct 04
2024
|
Bvf Partners L P Director |
SELL
Open market or private sale
|
Direct |
2,000,000
-9.26%
|
$100,000,000
$50.0 P/Share
|
|
Oct 04
2024
|
Simon Sturge Director |
SELL
Open market or private sale
|
Direct |
171,000
-49.86%
|
$9,063,000
$53.72 P/Share
|
|
Feb 29
2024
|
Da Silva Jorge Santos Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,740
-0.16%
|
$260,700
$55.89 P/Share
|
|
Feb 28
2024
|
Da Silva Jorge Santos Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
56,065
-1.84%
|
$3,083,575
$55.0 P/Share
|
|
Feb 28
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
28,090
-40.09%
|
$1,544,950
$55.0 P/Share
|
|
Feb 28
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
31,910
-1.08%
|
$1,755,050
$55.0 P/Share
|
|
Feb 27
2024
|
Da Silva Jorge Santos Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
62,810
-2.02%
|
$3,454,550
$55.0 P/Share
|
|
Feb 27
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
29,431
-29.58%
|
$1,618,705
$55.0 P/Share
|
|
Feb 27
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
29,491
-0.99%
|
$1,622,005
$55.0 P/Share
|
|
Feb 21
2024
|
Da Silva Jorge Santos Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,125
-0.04%
|
$61,875
$55.27 P/Share
|
|
Feb 21
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
569
-0.57%
|
$31,295
$55.3 P/Share
|
|
Feb 21
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
509
-0.02%
|
$27,995
$55.31 P/Share
|
|
Feb 20
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-9.09%
|
$570,000
$57.43 P/Share
|
|
Feb 20
2024
|
Kristian Reich Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-0.33%
|
$570,000
$57.45 P/Share
|
|
Feb 20
2024
|
Da Silva Jorge Santos Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-0.64%
|
$1,140,000
$57.44 P/Share
|
|
Feb 16
2024
|
Da Silva Jorge Santos Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-0.64%
|
$1,200,000
$60.15 P/Share
|
Last 12 Months Summary
Buy / Acquisition
303K
Shares
From
3
Insiders
| Grant, award, or other acquisition | 192K shares |
|---|---|
| Conversion of derivative security | 112K shares |
Sell / Disposition
2.28M
Shares
From
3
Insiders
| Open market or private sale | 2.17M shares |
|---|---|
| Sale (or disposition) back to the issuer | 112K shares |